Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pipex Pharmaceuticals has filed a new drug application with the FDA for its lead drug candidate Coprexa for the treatment of initially presenting neurologic Wilson's disease.
Subscribe to our email newsletter
Coprexa is an oral, small-molecule, anti-copper agent that is highly specific for the reduction of free copper in serum, the most toxic form of copper in the body, and is thus suited for the treatment of central nervous system (CNS) diseases in which abnormal serum and CNS copper homeostasis are implicated.
Steve Kanzer, Pipex’s chairman and CEO, said: “This new drug application (NDA) filing represents a transforming event for Pipex as well as an important potential new treatment option for initially presenting neurologic Wilson’s disease patients.
“In addition to making this potential new treatment option available to initially presenting neurologic Wilson’s disease patients, we look forward to increasing awareness of this debilitating disease that is all too often misdiagnosed for years or, if diagnosed at all, is diagnosed too late to save these patients’ lives.”